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Background: Trabectedin and thioglitazones have been documented to induce adipocytic maturation in myxoid
liposarcoma; we have noted this in our experience as well. Intriguingly, we have also encountered this same
phenomenon in myxoid liposarcomas exposed to various combinations of neoadjuvant doxorubicin and ifosfamide
systemic chemotherapy with preoperative radiation, where the pathological effects have been less characterized.
We examined the histological changes, including adipocytic maturation, associated with this treatment in patients
with myxoid liposarcoma and evaluated for prognostic significance.
Methods: Twenty-two patients were identified with histologically confirmed myxoid liposarcomas (9 with variable
hypercellular areas) who were treated with neoadjuvant doxorubicin (75-90 mg/m2/continous infusion over 72h
every 3 week) and ifosfamide (2.5 g/m2 daily x 4 every 3 weeks) for 4-6 cycles. Twenty-one patients received
pre-operative radiation including 5 with concurrent gemcitabine. Pre- and post-treatment MRI studies were
compared for changes in tumor area, fat content and contrast uptake, with the latter two estimated as: none,
<25%, 25-49% and >50%. Post-treatment specimens were evaluated for hyalinization, necrosis and adipocytic
maturation. Clinical follow-up was obtained.
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Results: Median age was 45 (26-72) years with a median tumor size of 11 (2-18) cm. All occurred in the lower
extremities except for one case in the neck. As is common in myxoid liposarcoma, all had extensive treatment
changes (>90%) with extensive hyalinization (n = 16; >90%) or prominent adipocytic maturation (n = 6; >50%)
including 2 cases composed almost entirely of mature-appearing adipose tissue. Variable necrosis was identified
(5-30%). MRI revealed a decrease in tumor area in all but one tumor (median, 65%), an increase in fat content in 7
tumors (n = 2, >50%;n = 2, 25-50%;n = 3,<25%), and a decrease in contrast enhancement in most tumors
(n = 5, >50%; n = 9, 25-49%; n = 7, <25%). Median follow-up was 57 (12-96) months with 17 alive with no
disease/metastases, 3 alive with disease and 2 dead of disease. Six patients developed metastases with median
interval of 26 (22-51) months post resection. Four of 6 tumors with increased adipocytic maturation >50% on
histology had increased fat detected by MRI (>25%). All 6 are alive but 2 developed metastases. In the remaining
patients, 4 developed metastases with 14 alive and 2 dead of disease.
Conclusion: Myxoid liposarcoma exposed to neoadjuvant doxorubicin and ifosfamide and pre-operative radiation
can have prominent adipocytic maturation similar to trabectedin treatment. Myxoid liposarcomas exhibit extensive
treatment changes with prominent hyalinization being the most common histological change. Despite this,
patients develop metastases regardless of adipocytic maturation. While of unclear significance, no patient with fatty
maturation died of disease.
Keywords: Adipocytic maturation, Myxoid liposarcoma, TreatmentFigure 1 Myxoid liposarcoma metastasis in a patient being
treated with trabectedin. Histological sections reveal irregularly-
sized mature-appearing adipocytes in a myxoid stroma with thin-
walled vessels. Adipocytic maturation is seen in patients receiving
trabectedin therapy.Background
Myxoid liposarcoma is the second most common malig-
nant lipomatous tumor and preferentially affects ages
younger than most other liposarcomas (young adults),
and typically occurs in the lower extremities. Classically,
these tumors are characterized by monotonous small
short spindle cells in myxoid stroma with abundant
thin-walled capillaries. Scattered lipoblasts, typically uni-
vacuolar, are variably present sometimes accompanied
by variable amounts of more mature-appearing adipo-
cytes [1,2]. Despite their banal histological appearance,
metastases are common, and often to peculiar sites such
as to the retroperitoneum and bone [3,4]. Tumors with
increased hypercellular areas composed of enlarged,
more round tumor cells without intervening myxoid
stroma have an increased risk for metastases and poor
prognosis [2-6]. Those with a significant proportion of
round cell change are termed round cell liposarcoma
and considered to be a higher grade variant of myxoid
liposarcoma [7].
The vast majority of myxoid liposarcomas are charac-
terized by a recurrent translocation involving t(12;16)
(q13;p11) fusing the 30-end promoter region of FUS/TLS
(16p11) with the 50-end of the CHOP/DDIT3 locus
(12q13) [8-14]. The resulting fusion protein is believed
to play a critical role in tumorigenesis, blocking the
PPARγ pathway which promotes adipocytic differentiation
or maturation, offering insight into the primitive pre-
adipocytic histological appearance of this tumor [15,16].
In rare situations, the alternative t(12;22) (q13;p11)
resulting in a EWSR1-CHOP/DDIT3 fusion transcript is
present [9,17-20]. Other genetic mutations including in-
volvement of the p53, RET, MET, and PI-3 kinasepathways, have also been implicated in myxoid liposar-
comas [6,15,16,21-23].
ET-743 (also known as trabectedin) is an alkaloid
compound discovered from the sea squirt Ecteinascidia
turbinata and found to show efficacy in the treatment of
sarcoma patients including those with myxoid liposar-
coma [24-27]. While the mechanism of action is not
completely known, trabectedin may block transcription fac-
tor binding to the fusion gene FUS-CHOP/DDIT3 [15]. It
has also been well documented to induce differentiation in
myxoid liposarcoma with prominent adipocytic maturation
(Figure 1). In addition, PPARγ agonists, thioglitazones, have
been reported to produce similar histological effects in
Table 1 Summary of clinical, pathological and imaging
factors






Round Cell Component (n,range of %) n = 9 (5-30%)
Follow-up
Median, range 57 mos (12-96 mos)
Alive and Well (median, range) n = 17 (35 mos, 12-96 mos)
Alive with Disease (range) n = 3 (61,67, 72 mos)
Dead of Disease (range) n = 2 (82, 16 mos)
Metastases (median, range) n = 6 (26,
22-51 mos)
Post-Treatment Pathological Findings
Median Size (range) 11 (2-18) cm
Tumor with Treatment Changes
(median %, range)
95% (90-95%)
Hyalinization (median %, range) 90% (10-95%)
Fat Maturation
Median (range)% 10% (5-90%)
Prominent >50% (n) n = 6 with 2 >90%
Necrosis (median %, range) 5% (5-10%)
Radiological Changes
Decrease in Tumor Size
(median % decrease, range)
65% (30 - 94%)*
Fat Amount Change
(n, % of cases with changes)
Decrease <25% 1 (4.5%)
No change 14 (63.6%)
Increase <25% 3 (13.6%)
Increase 25-49% 2 (9.1%)
Increase >50% 2 (9.1%)
Contrast Media Change
(n, % of cases with changes)
Increase <25% 1 (4.5%)
Decrease <25% 7 (31.8%)
Decrease 25-49% 9 (40.9%)
Decrease >50% 5 (22.7%)
* One specimen had an increase in size (17%).
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ported to be characteristic and perhaps specific and thus
suggesting a particular mechanism of action leading to the
release of a blockade of adipocytic maturation in the tumor.
We have encountered this phenomenon of adipocytic
maturation in myxoid liposarcomas exposed to neoadju-
vant doxorubicin and ifosfamide and pre-operative radi-
ation, where the pathological effects have been less
characterized. We examined the histological changes, in-
cluding adipocytic maturation, associated with this treat-
ment in patients with myxoid liposarcoma and evaluated
for any prognostic significance of this feature.
Methods
Under institutional board review approval, twenty-two
patients were identified between 2000 and 2009 who had
histologically confirmed (WLW, AJL) myxoid liposar-
coma on pre-treatment biopsy and were not previously
treated with chemotherapy. Nine of these patients had
variable hypercellular/round cell change. Patients were
treated with neoadjuvant doxorubicin (75-90 mg/m2/
continous infusion over 72 hours every three weeks) and
ifosfamide (2.5 g/m2 over three hours for four days,
every three weeks) for 4-6 cycles. Twenty-one patients
also received preoperative radiation including 5 with
concurrent gemcitabine. Pre- and post-treatment MRI
studies were compared (JM) for changes in tumor area,
fat content and contrast uptake, with the latter two esti-
mated as: none, <25%, 25-49% and >50%. Post-treatment
specimens were compared with pre-treatment biopsies
and evaluated for percentage of hyalinization, necrosis
and adipocytic maturation (WLW, AJL). Clinical follow-
up was obtained. Fluorescence in situ hybridization
(FISH) on a selected post-treatment case for 12q13 to
detect CHOP/DDIT3 rearrangement was performed
using the LSI FUS dual-color, break-apart probe
(Abbott Molecular/Vysis, Des Plaines, IL, USA)
according to the manufacturer’s recommendations as
previously described [14].
Results
Clinical, pathological and radiological findings are sum-
marized in Table 1. The median age was 45 (26-72) years
with a median size of 11 (2-18) cm. All occurred in the
lower extremities except for one case in the neck.
All developed extensive post-treatment changes
(>90%) with extensive hyalinization (>90%) being the
most common change seen (16/22 patients, 72%) (Figure 2).
Focal residual areas of characteristic vascular pattern were
often identified. Prominent fatty maturation (>50%) was
seen in 6/22 (27%) cases including 2 cases composed al-
most entirely of mature-appearing fat (Figure 3). Both cases
received radiation therapy; one also received gemcitabine.
One tumor with extensive post-treatment fatty maturationwas tested and found to retain the rearrangement in
CHOP/DDIT3 verifying that the mature adipocytes
arose from the tumor cells. Variable necrosis was also
identified (5-30%).
MRI revealed a decrease in tumor area in all but one
tumor (median decrease in size was 65%). A decrease
in contrast enhancement was found in most tumors
Figure 2 (A) Pre-treatment biopsy reveals characteristic bland spindle cells in myxoid stroma with branching thin walled vessels. (B)
Post treatment specimen reveals extensive hyalinization that is essentially acellular. This was the most common pattern seen in treated tumors.
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tologically corresponding to increased hyalinization,
decreased cellularity and decreased vasculature. Seven
tumors developed an increase in a register characteris-
tic of mature adipose tissue (n = 2,>50%; n = 2, 25-49%;
n = 3,<25%) (Figure 5). Four of 6 tumors with histo-
logical adipocytic maturation >50% also had increased
adipose signal detected by MRI (>25%).
Median follow-up was 57 (12-96) months with 17
patients alive with no disease/metastases, 3 patients alive
with disease and 2 patients dead of disease. Six patients
developed metastases with a median interval of 26 (22-51)
months post resection. All 6 patients with adipocytic mat-
uration are alive although 2 developed metastases.
Conclusions
Myxoid liposarcomas treated with neoadjuvant doxo-
rubicin and ifosfamide and pre-operative radiation con-
sistently develop extensive treatment effect that canFigure 3 Histological example of extensive fatty maturation
with variable sized adipocytes. Extensive fatty maturation was
seen in one-third of cases; two of which had adipocytic maturation
that was greater than 90%.include adipocytic maturation as demonstrated on MRI
imaging and confirmed histologically at resection. In our
series, the most common treatment change was exten-
sive hyalinization (16/22, 72%) with decreased vasculature
as seen in other studies [29]. In addition, approximately
one-third of our patients also developed prominent adi-
pocytic maturation, comprising more than 50% of the
treated tumor. Two tumors had extensive adipocytic
differentiation giving a misleading appearance of a well-
differentiated liposarcoma or even a benign lipoma.
Fortunately, most tumors also harbored areas of hyalini-
zation, characteristic of treated myxoid liposarcoma.
They also lacked the fibrous bands with scattered pleo-
morphic cells seen in most well-differentiated liposarcomas.
Molecular testing, either for rearrangements involving
CHOP/DDIT3 by fluorescence in-situ hybridization assay
or reverse polymerase chain reaction for the specific fusion
transcripts, can also be helpful in confirming the diagnosis
of myxoid liposarcoma [14,30]. In our study, rearrangement
was still identified in tumors with prominent fatty differen-
tiation by fluorescence in-situ hybridization assay. We
chose this modality since it allows one to determine the cel-
lular component of the tissue showing the re-arrangement.
Well-differentiated liposarcomas would lack this rearrange-
ment and would instead demonstrate amplification of the
12q13-15 region [31].
The phenomenon of adipocytic maturation is compar-
able to myxoid liposarcomas in patients treated with tra-
bectedin and the thioglitazone family of PPARγ agonists.
In 2007, Grosso and colleagues described the develop-
ment of “mature lipoblast-featuring cells” and “clear adi-
pocytic differentiation” in myxoid liposarcomas treated
with trabectedin [24]. Gronchi and colleagues reported
maturation to lipoblasts, decreased cellularity and vascu-
larity in the tumors of 16 of 23 patients who received
neoadjuvant trabectedin for advanced localized myxoid
liposarcomas [32]. Forni and colleagues saw similar find-
ings in myxoid liposarcoma cell lines and two patients
treated with trabectedin [33]. Similarly, Demetri and
Figure 4 Example of MRI findings seen in the majority of myxoid liposarcomas undergoing treatment in our series. T1 weighted axial
image of the calf with mass (A) pre-treatment and (B) post treatment showing a reduction in tumor size and decreased adipocytic content. T1
weighted post contrast media with fat saturation with (C) pre-treatment demonstrating an extensive heterogeneous enhancement, while (D)
post treatment shows decreased tumor size and decreased enhancement greater than 50%. These findings correspond to increased hyalinization
and decreased vascularity histologically.
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six weeks in tumors from three patients treated with tro-
glitazone, a PPARγ agonist. These changes coincided
with an increased expression in mRNA associated with
adipocytic differentiation including AP2, adipsin and
PPARγ. Mild increase in adipose density signaling was
also seen in these tumors on MRI imaging [28]. In our
series, extensive treatment changes, predominantly hya-
linization with decreased cellularity and vascularity, was
seen in the tumors of our patients treated with doxo-
rubicin and ifosfamide with pre-operative radiation ther-
apy. However, adipocytic maturation was also seen in
our tumors, histologically indistinguishable to what has
been reported previously reported by others and also
seen by us in myxoid liposarcoma tumors treated with
trabectedin (WLW, AJL, PT). In most cases, MRI im-
aging correlated with evolution of treatment changes
seen in the resection specimen. Decreased vascularity by
contrast media enhanced imaging was seen in the major-
ity of cases with extensive hyalinization and subsequent
decrease of the thin-walled vessels in these areas. In
addition, all four cases that had an increase of fat (>25%)
by MRI also showed prominent adipocytic maturation
on histological resection.
Myxoid liposarcoma can rarely have areas with
mature-appearing adipocytes as well. Evans reported 29cases of myxoid liposarcoma, some of which had areas
that were reported to resemble mature, non-neoplastic
adult adipose tissue [1]. In a more recent study by
Fritchie and colleagues, 10 of 46 (22%) myxoid liposarco-
mas had a mature fat appearing lipomatous component
that composed 5-79% of the tumor. Full information
regarding treatment was not provided in either study. Some
degree of stromal hyalinization was also observed in seven
cases in the Fritchie study, six of which were known to be
untreated. However, this was only focal, composing only
1-9% of these tumors, in contrast to our treated cases
which had extensive hyalinization [7]. It is possible that
some changes could have been present before treatment
and not sampled in the pre-treatment biopsy, emphasizing
the importance of comparing pre- and post-treatment im-
aging studies. One case with histological evidence of adipo-
cytic maturation revealed no change in adipocytic content
by MRI and adipocytic maturation was noted in the pre-
treatment biopsy. However, in our experience (WLW, AJL)
extensive fatty maturation and hyalinization are uncommon
in untreated myxoid liposarcomas. The remaining pre-
treatment biopsies lacked these changes and developed
increased fat on MRI studies between pre- and post
treatment tumors, which corresponded histologically to
increased fatty maturation, increased hyalinization and
decrease vascularity on the resection specimen.
Figure 5 MRI findings in a case of myxoid liposarcoma which developed extensive adipocytic maturation during treatment. T1
weighted coronal right thigh (A) pre-treatment and (B) post treatment demonstrating a marked decrease in tumor size. T1 weighted axial image
of right thigh (C) pre-treatment and (D) post treatment demonstrate an increase in signal characteristic of mature adipose tissue content (>50%)
with reduction in size. T1 weighted axial with contrast media and fat saturation (E) pre-treatment showing large mass with extensive vascular
enhancement. (F) Post treatment scans show a reduction in size of mass and a decrease in vascular enhancement greater than 50%.
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No patients with extensive adipocytic maturation died of
disease, but patients did develop metastases regardless
of adipocytic maturation. However, our series is small
and additional larger studies are necessary. The mechan-
ism of fatty maturation when exposed to doxorubicinand ifosfamide and radiation therapy is also not known.
Doxorubicin is an anthracycline and proposed to have
many mechanisms of actions among which include
intercalcating DNA, formation of free radicals, inhibition
of topoisomerase II, prohibiting DNA and RNA unwinding,
and induction of cell death [34]. Ifosfamide is a DNA
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results in cell death [35]. Interestingly, doxorubicin at low
concentrations has been reported to induce differentiation
in leukemia and breast carcinoma cell lines [34,36,37]. In
breast cell lines, differentiation corresponded to the reduc-
tion in c-myc expression and growth arrest in response to
doxorubicin induced DNA damage [37]. To our knowledge,
ifosfamide has not been reported to induce differentiation.
Perhaps a similar non-specific response to DNA damage
with doxorubicin can occur in myxoid liposarcomas. Other
sarcomas have also been reported to differentiate in
response to chemotherapy and radiotherapy including
rhabdomyosarcoma [38]. Our study would support the
notion that these changes can be a general response to
effective treatment in myxoid liposarcoma and may
not necessarily be specific to a treatment modality
such as trabectedin. In this context, we should be cau-
tious in interpreting potential insights into the un-
known mechanism of action of trabectedin from this
phenomenon.
The fusion transcript characteristic in the vast majority of
myxoid liposarcomas is composed of FUS, which encodes
for a RNA/DNA binding domain, and CHOP/DDIT3,
which encodes for a transcription factor which dimerizes
with CAAT/enhancer binding proteins (C/EBP) and nega-
tively regulates genes involved in adipocytic differentiation
including PPARγ. Multiple fusion variants and types exist;
however, none have been associated with increased adipo-
genesis [39]. Trabectedin binds to the minor groove of
DNA and is theorized to sterically hinder the binding
of the FUS-CHOP/DDIT3 fusion protein (probably
mediated primarily by the CHOP/DDIT3-donated
DNA binding domain) and thus allow adipocytic dif-
ferentiation to continue by relieving repression. It
could also effect the post transcriptional modification
of the fusion transcript [15]. In addition, other muta-
tions are known to exist including activation of the
ERK/MAPK, PI-3-kinase/Akt pathways, alterations of
p53, IGF1R and IGF2; some of these have been asso-
ciated with round cell change and poor prognosis.
[16,22] None are known to correlate with adipocytic
differentiation.
In summary, we report the histological and radio-
logical findings seen in myxoid liposarcomas in patients
treated with doxorubicin and ifosfamide and pre-
operative radiation therapy. The vast majority of these
tumors demonstrated significant treatment effect in the
form of hyalinization; however, adipocytic maturation,
once thought to be exclusive to tumors treated with tra-
bectedin and PPARγ agonists, were also seen in some of
our cases. Pathologists and radiologists should be aware
of this as it may cause diagnostic confusion if prior his-
tory is not available and in comparing histological treat-
ment changes between trials.Competing interests
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